{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:55:51Z","timestamp":1792425351729,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T00:00:00Z","timestamp":1445644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10067-015-3099-3","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T00:53:51Z","timestamp":1445648031000},"page":"2141-2145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom"],"prefix":"10.1007","volume":"34","author":[{"given":"Muhammad K.","family":"Nisar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneesa","family":"Rafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J. K.","family":"\u00d6st\u00f6r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,24]]},"reference":[{"key":"3099_CR1","first-page":"17","volume":"254","author":"MK Nisar","year":"2010","unstructured":"Nisar MK, \u00d6st\u00f6r AJK (2010) Disease remission the goal of therapy in rheumatoid arthritis. Practitioner 254:17\u201321","journal-title":"Practitioner"},{"key":"3099_CR2","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1093\/rheumatology\/ker289","volume":"50","author":"AV Hadjinicolaou","year":"2011","unstructured":"Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, \u00d6st\u00f6r AJK (2011) Noninfectious pulmonary complications of newer biological agents for rheumatic diseases\u2014a systematic literature review. Rheumatology 50:2297\u20132305","journal-title":"Rheumatology"},{"key":"3099_CR3","first-page":"1436","volume":"30","author":"L Carmona","year":"2003","unstructured":"Carmona L, Hernandez-Garcia C, Vadillo C et al (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30:1436\u20131439","journal-title":"J Rheumatol"},{"key":"3099_CR4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"3099_CR5","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R et al (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2:CD008794","DOI":"10.1002\/14651858.CD008794.pub2"},{"key":"3099_CR6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69:522\u2013528","journal-title":"Ann Rheum Dis"},{"key":"3099_CR7","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/rheumatology\/keq249a","volume":"49","author":"T Ding","year":"2010","unstructured":"Ding T, Ledingham J, Luqmani R et al (2010) BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 49:2217\u20132219","journal-title":"Rheumatology"},{"key":"3099_CR8","unstructured":"NICE CG117. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. https:\/\/www.nice.org.uk\/guidance\/cg117"},{"key":"3099_CR9","doi-asserted-by":"crossref","unstructured":"(2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-a treatment. Thorax 60:800\u2013805","DOI":"10.1136\/thx.2005.046797"},{"key":"3099_CR10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"JJ Gomez-Reino","year":"2007","unstructured":"Gomez-Reino JJ, Carmona L, Angel Descalzo M et al (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57:756\u2013761","journal-title":"Arthritis Rheum"},{"key":"3099_CR11","unstructured":"Public Health England Tuberculosis in the UK 2014 report. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/360335\/TB_Annual_report__4_0_300914.pdf"},{"key":"3099_CR12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1741-7015-11-97","volume":"11","author":"SV Ramagopalan","year":"2013","unstructured":"Ramagopalan SV, Goldacre R, Skingsley A, Conlon C, Goldacre MJ (2013) Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies. BMC Med 11:97","journal-title":"BMC Med"},{"key":"3099_CR13","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","volume":"36","author":"I Solovic","year":"2010","unstructured":"Solovic I, Sester M, Gomez-Reino JJ et al (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36:1185\u20131206","journal-title":"Eur Respir J"},{"key":"3099_CR14","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/cid\/ciu104","volume":"58","author":"SA Novosad","year":"2014","unstructured":"Novosad SA, Winthrop KL (2014) Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae. Clin Infect Dis 58:1587\u20131598","journal-title":"Clin Infect Dis"},{"key":"3099_CR15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72:1613\u20131620","journal-title":"Ann Rheum Dis"},{"key":"3099_CR16","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","volume":"63","author":"KL Hyrich","year":"2004","unstructured":"Hyrich KL, Silman AJ, Watson KD, Symmons D (2004) Anti-tumour necrosis factor in rheumatoid arthritis\u2014an update on safety. Ann Rheum Dis 63:1538\u20131543","journal-title":"Ann Rheum Dis"},{"key":"3099_CR17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risks: mechanisms of action and clinical management. Lancet Infect Dis 3:148\u2013155","journal-title":"Lancet Infect Dis"},{"key":"3099_CR18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","volume":"43","author":"P Brassard","year":"2006","unstructured":"Brassard P, Kezouh A, Suissa S (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43:717\u2013722","journal-title":"Clin Infect Dis"},{"key":"3099_CR19","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60:1884\u20131894","journal-title":"Arthritis Rheum"},{"key":"3099_CR20","first-page":"247","volume":"31","author":"JE Fonseca","year":"2006","unstructured":"Fonseca JE, Canhao H, Silva C et al (2006) Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience. Acta Reumatol Port 31:247\u2013253","journal-title":"Acta Reumatol Port"},{"issue":"Suppl3","key":"3099_CR21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/annrheumdis-2013-eular.2972","volume":"72","author":"I Mahmoud","year":"2013","unstructured":"Mahmoud I, Dridi L, Saidane O et al (2013) Latent TB screening and management before biologic agents instauration and risk of reactivation: the experience of an endemic TB country. Ann Rheum Dis 72(Suppl3):987","journal-title":"Ann Rheum Dis"},{"key":"3099_CR22","doi-asserted-by":"crossref","unstructured":"Rosales Rosado Z, Gomez A, Pena R et al (2014) Incidence of tuberculosis in RA treated with biological agents. Ann Rheum Dis (Suppl2)","DOI":"10.1136\/annrheumdis-2014-eular.4517"},{"issue":"4","key":"3099_CR23","first-page":"08","volume":"24","author":"M Vega De La","year":"2013","unstructured":"De La Vega M, Gomez G, Casado G et al (2013) Argentinian Register of biologics treatments (BIOBADASAR) adverse events report. Rev Arg Reumatol 24(4):08\u201314","journal-title":"Rev Arg Reumatol"},{"key":"3099_CR24","author":"EV Arkema","year":"2014","unstructured":"Arkema EV, Jonsson J, Baecklund E et al (2014) Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis. doi: 10.1136\/annrheumdis-2013-204960","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3099-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-015-3099-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3099-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T17:55:03Z","timestamp":1567274103000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-015-3099-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,24]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["3099"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-3099-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,24]]}}}